Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | F10 | P00742 | 10/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6381640 | 0.91 | MAPT (0.51) | MEN1ALDH1A1LMNAMAPTMAPK1 | |
| SCHEMBL6381233 | 0.91 | MAPT (0.51) | MEN1ALDH1A1LMNAMAPTMAPK1 | |
| SCHEMBL6375037 | 0.91 | MAPT (0.51) | MEN1ALDH1A1LMNAMAPTMAPK1 | |
| SCHEMBL6381537 | 0.89 | MAPT (0.49) | MEN1ALDH1A1LMNAMAPTMAPK1 | |
| SCHEMBL6381542 | 0.89 | MAPT (0.49) | MEN1ALDH1A1LMNAMAPTMAPK1 | |
| SCHEMBL6374121 | 0.87 | MEN1 (0.49) | MEN1ALDH1A1LMNAMAPTMAPK1 | |
| SCHEMBL6379655 | 0.87 | MEN1 (0.49) | MEN1ALDH1A1LMNAMAPTMAPK1 | |
| SCHEMBL6380569 | 0.87 | MEN1 (0.49) | MEN1ALDH1A1LMNAMAPTMAPK1 | |
| SCHEMBL6376174 | 0.85 | MEN1 (0.52) | MEN1ALDH1A1LMNAMAPTMAPK1 | |
| SCHEMBL6376163 | 0.85 | MEN1 (0.52) | MEN1ALDH1A1LMNAMAPTMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050137230-A1 | Carboxamide derivatives | DORSCH DIETER (DE) | 2005-06-23 | — | — | US | claimed |
| US-20040038858-A1 | Carboxamide derivatives and their use in the treatment of thromboembolic diseases and tumours | MERCK PATENT GMBH (DE) | 2004-02-26 | — | — | US | claimed |
| US-20050137230-A1 | Carboxamide derivatives | DORSCH DIETER (DE) | 2005-06-23 | — | — | US | disclosed |
| US-20040038858-A1 | Carboxamide derivatives and their use in the treatment of thromboembolic diseases and tumours | MERCK PATENT GMBH (DE) | 2004-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050137230-A1 | Carboxamide derivatives | F11, F12, F2 | MEN1 218/4885ALDH1A1 832/4885LMNA 436/4885 |
| US-20040038858-A1 | Carboxamide derivatives and their use in the treatment of thromboembolic diseases and tumours | CNR2, CNR1, HCAR2 | MEN1 3354/4885ALDH1A1 1757/4885LMNA 445/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.